At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
PF-06882961 20MGdrug
Likely dose
PF-06882961 20MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Non-randomized, Open-label, Single-dose, Parallel Cohort Study to Compare the Pharmacokinetics of PF-06882961 in Adult Participants With Varying Degrees of Hepatic Impairment Relative to Participants Without Hepatic Impairment.
In Brief
A Phase 1 clinical trial evaluating PF-06882961 20MG for Hepatic Impairment and Healthy Volunteers. Completed, enrolled 24 participants across 2 sites.
Detailed Summary
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma Pharmacokinetic (PK) of PF-06882961
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Impairment, Healthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartDec 2020
Primary CompletionJan 2022
TodayJul 2026
First PostedOct 27, 2020
Enrollment StartDec 30, 2020
Primary CompletionJan 10, 2022
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 5.7 years ago
Interventions
PF-06882961 20MGdrug
PF-06882961 in 20 mg oral tablet will be administered on Day 1